Skip to main
  1. Stocks
  2. PROCEPT BioRobotics Corp
  3. Forecast
PRCT

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 45%
Hold 36%
Sell 9%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics is supported by improving commercial execution, as HYDROS accounts generated procedure volumes more than 35% higher than legacy AquaBeam accounts in 3Q26, signaling stronger utilization from the newer installed base. The replacement program is also ahead of expectations, with 20 replacement systems placed in the quarter and 36 YTD, while approximately 70% of systems were launched by the dedicated launch team and handpiece sales returned to above a 1:1 ratio with procedures, suggesting inventory normalization has stabilized. Strong new-system ASP of about $495k and international revenue growth of 32% y/y further reinforce the outlook, with upside tied to continued utilization gains and the growing mix of HYDROS across the installed base.

Bears say

PROCEPT BioRobotics is facing a weaker-than-expected growth backdrop, as 3Q26 sales of $98.3mn missed consensus and U.S. procedure utilization remained down ~9% y/y, underscoring soft demand for its core Aquablation franchise. New-system placements were especially concerning, with only 42 new systems sold versus an estimated 54, while 140 YTD U.S. net additions and the need for ~70 greenfield systems in 4Q26 to exceed the full-year target highlight elevated execution risk. Despite gross margin of 66.3% and solid handpiece sales, the company’s negative outlook is driven by compressed EBITDA margins, dependency on a sharp 4Q step-up, and rising competitive and reimbursement pressure from PAE.

PRCT has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

PRCT Analyst Forecast & Price Prediction

Get the latest PRCT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRCT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Hold based on their latest research and market trends.

According to 11 analysts, PRCT has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


PRCT Analyst Forecast & Price Prediction

Get the latest PRCT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PRCT

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PRCT stock data and trends